Key Points
ImmunityBio's bladder cancer treatment could soon gain approval for use in many new cases.
This expanded base of patients to help could keep the company's triple-digit sales growth going strong.
ImmunityBio has significant potential through its pipeline and today's news, but its stock has already quadrupled this year.
- 10 stocks we like better than ImmunityBio ›
Shares of immunotherapy biotech ImmunityBio (NASDAQ: IBRX) initially popped today, and are up 9% as of 10:45 a.m. ET on Wednesday. After market close yesterday, ImmunityBio announced that the Food and Drug Administration (FDA) had accepted the company's supplemental biologics license application (BLA) for review, which could lead to a major label expansion for its core treatment, Anktiva.
Currently, ImmunityBio's flagship Anktiva drug is approved to treat patients with bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) who have Carcinoma in Situ (CIS). The new BLA would expand Anktiva's label to include its use in treating BCG-unresponsive NMIBC cases with papillary disease, in addition to CIS. Plenty of technical terms here, but this could be a big deal for ImmunityBio, so it is worth looking into for the following reason.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
In the press release, management noted, "Approximately 85% of the 64,000 people diagnosed with NMIBC in the U.S. each year present with papillary disease." Papillary disease is much more common than CIS, so this could greatly expand ImmunityBio's target market as it continues to grow its treatment indications. Since "CIS and papillary disease arise from the same cancer-inducing clone," many doctors have already been treating patients off-label with Anktiva. An FDA approval would cause insurers to cover the treatment going forward.
The FDA set a Prescription Drug User Fee Act (PDUFA) target action date for Jan. 6, 2027, so investors will want to keep this date in mind going forward. In addition to its bladder cancer treatments, ImmunityBio has a strong pipeline of clinical trials spanning lung and ovarian cancer, HIV, glioblastoma, Non-Hodgkin Lymphoma, and more. That said, ImmunityBio's stock has more than quadrupled year to date and currently trades at 58 times sales, so a lot of this potential is already priced into the company's valuation. Investors would be wise not to go "all-in" at once if they're interested in the promising biotech, but rather to make smaller bets over time.
Should you buy stock in ImmunityBio right now?
Before you buy stock in ImmunityBio, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ImmunityBio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $481,750!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,352,457!*
Now, it’s worth noting Stock Advisor’s total average return is 990% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 20, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
